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Abstract: Barth syndrome (BTHS) is a rare, X-linked, mitochondrial disorder caused by mutations
in the gene encoding tafazzin. BTHS results in cardiomyopathy, muscle fatigue, and neutropenia
in patients. Tafazzin is responsible for remodeling cardiolipin, a key structural lipid of the inner
mitochondrial membrane. As symptoms can vary in severity amongst BTHS patients, we sought to
compare mtDNA copy numbers, mitochondrial fragmentation, and functional parameters between
primary dermal BTHS fibroblasts isolated from patients with two different mutations in the TAZ locus.
To confirm cause-effect relationships and further support the development of gene therapy for BTHS,
we also characterized the BTHS cells following adeno-associated virus (AAV)-TAZ transduction.
Our data show that, in response to AAV-TAZ transduction, these remarkably dynamic organelles
show recovery of mtDNA copy numbers, mitochondrial structure, and mitochondrial function,
providing additional evidence to support the therapeutic potential of AAV-mediated gene delivery for
BTHS. This study also demonstrates the direct relationship between healthy mitochondrial membrane
structure and maintenance of proper levels of mtDNA copy numbers.
Keywords: Barth syndrome; mitochondrial disease; mtDNA copy numbers; gene therapy; AAV;
TMEM65; fibroblasts
1. Introduction
Barth syndrome (BTHS) is a rare mitochondrial disorder caused by recessive loss-of-function
mutations in the nuclear-encoded gene TAZ, which encodes tafazzin. Tafazzin is an acyltransferase
that is trafficked to the inner mitochondrial membrane (IMM) where it remodels monolysocardiolipin
(MLCL) to mature cardiolipin (CL) [1,2]. A critical phospholipid, CL is involved in maintenance of
mitochondrial membrane structure and fluidity, osmotic stability, and efficient electron transport chain
(ETC) function [3–6]. In BTHS mitochondria, the increased MLCL/CL ratios result in an unstable IMM
structure and ultimately, inefficient ETC-mediated ATP production [7–9]. Typical BTHS symptoms
include cardioskeletal myopathy, impaired cardiac and skeletal muscle bioenergetics, neutropenia,
and 3-methylglutaconic aciduria, with cardiomyopathy being the primary cause of death [10–16].
Two primary, non-SV40 transformed, dermal BTHS fibroblast lines that represent different
mutations in the TAZ locus: BTHS1 (c.170G>T in exon 2—missense mutation), BTHS 2 (c.140-152del13
in exon 2—frameshift mutation), and 2 healthy control lines were used in this study [6,17,18].
Although the structural integrity of the IMM is known to be impaired in BTHS, investigations into
Int. J. Mol. Sci. 2019, 20, 3416; doi:10.3390/ijms20143416 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2019, 20, 3416 2 of 12
levels of mtDNA copy numbers in BTHS and whether these levels successfully recover following
a gene replacement strategy in BTHS patient-derived cells have not yet been performed.
Clinical BTHS standard-of-care currently involves administration of diuretics and ACE inhibitors
and many patients eventually undergo cardiac transplantation. No disease-modifying therapies are
available for BTHS patients. Thus, we have been working to develop and test an adeno-associated
virus (AAV)-mediated gene therapy for delivery of the human TAZ gene. Recently, we demonstrated
the ability of this approach to significantly improve heart and skeletal muscle function in a mouse
model of BTHS using a wide variety of functional and quantitative proteomic analyses [19,20]. Here we
demonstrate the potential of this therapy in the background of two different mutations in the TAZ
locus and its direct impact on mtDNA copy numbers.
2. Results
2.1. BTHS Fibroblast Mitochondria Display Structural Alterations
The two BTHS fibroblasts lines used in this study represent either a missense mutation (BTHS1)
or a deletion with frameshift leading to premature stop (BTHS2) (Table 1).
Table 1. BTHS mutations.
DNA Mutation: Exon: Amino Acid: Mutation Type:
c.170G > T Exon 2 p.Arg57Leu Missense
c.140-152del13 Exon 2 p.Arg47Thr fs*32 Frameshift
Electron microscopy (EM) was performed and revealed more-diffuse and less-organized cristae
structures in both BTHS lines as compared to healthy controls (Figure 1A–C). Mitochondrial width
and area were significantly decreased in both BTHS lines (Figure 1D,E), while length was significantly
increased in both BTHS lines as compared to healthy controls (Figure 1F). Comparisons of mitochondrial
contour ratio calculations between the different lines revealed a significant increase in aspect ratios,
and a significant decrease in circularity and roundness ratios in the BTHS lines as compared to healthy
controls (Figure 1G–I).
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Figure 1. EM characterization of mitochondrial structures – Representative EM images from (A)
healthy controls, (B) BTHS1, and (C) BTHS2 fibroblast lines used to perform mitochondrial contour
evaluations (scale bar = 0.5 µm). Bar graphs representing mitochondrial (D) aspect ratios, (E) circularity
ratios, (F) roundness ratios, (G) solidity ratios, (H) width, and (I) alterations in various aspects of
mitochondrial contour in BTHS. (n ≥ 50 individual mitochondria for each measurement; data are
presented as mean + std. err. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.)
2.2. AAV-TAZ Administration Increases mtDNA Copy Numbers
Next, we sought to test how well we could transduce human dermal fibroblasts using the
previously described triple tyrosine mutant (Y–F) AAV capsid known to efficiently transduce cells
in vitro [21]. Both a control vector expressing eGFP and a therapeutic vector expressing TAZ were used
to treat BTHS fibroblasts at a multiplicity of infection (m.o.i.) of 50,000 vector genomes (v.g.) per cell
(Figure 2A). For this and all subsequent assays, cells were collected or assessed seven days post-AAV
transduction. TAZ gene expression was found to have increased more than 50-fold in both BTHS lines
following treatment with the AAV-TAZ vector as compared to cells treated with the same dose of the
control vector (Figure 2B).
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Figure 2. Vector design, TAZ gene expression, and mtDNA copy numbers – (A) Diagrams of the GFP
marker gene control (top) and human TAZ containing AAV vectors used in this study. ∆ITR on the
left represents the double-stranded version of AAV inverse terminal repeats. (B) TAZ gene expression
assay results demonstrate dramatic fold increase in expression over baseline for AAV-TAZ-treated
cells. (C) Relative mtDNA copy numbers in BTHS lines following AAV-eGFP (control vector—light
filled bars) or AAV-TAZ treatment (dark hashed bars) as compared to respective healthy control
levels. (D) TMEM65 gene expression results demonstrate significant increases in BTHS lines following
AAV-TAZ gene delivery. TAZ and TMEM65 gene expression levels were normalized to 18S expression
for all samples. (Data are presented as mean + std. err. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.)
Evaluations of relative mtDNA copy numbers amongst healthy and BTHS lines revealed
a significant decrease in mtDNA copy numbers in BTHS2 as compared to healthy controls (Figure 2C).
There was a significant increase in mtDNA copy numbers in both BTHS lines following AAV-TAZ
administration as compared to administration of the AAV-eGFP control vector. As we previously found
significant downregulation of the TMEM65 protein and its transcription levels in hearts from a mouse
model of BTHS, we also measured TMEM65 gene expression in these BTHS fibroblast lines and found
significantly decreased levels as compared to healthy controls (Figure 2D). In each case, TMEM65 gene
expression levels significantly increased following AAV-TAZ treatment.
2.3. Mitochondrial Fragmentation in BTHS
Immunofluorescence (IF) analysis of translocase of outer mitochondrial membrane 20 (TOMM20)
expression in healthy and BTHS lines enabled observations of mitochondrial distributions in cells
(Figure 3). In general, the mitochondria in healthy cells and in the AAV-TAZ-treated BTHS cells
appear to be more evenly distributed throughout the cytoplasm as compared to untreated BTHS cells,
where mitochondria display a more perinuclear localization (Figure 3A–F). Mitochondrial fragmentation
was assessed by gene expression analyses of YME1L1 and OMA—two markers of fragmentation that
were significantly upregulated in both BTHS lines as compared to healthy controls (Figure 3G,H).
Fragmentation gene expression levels were significantly improved in both BTHS lines following
transduction by AAV-TAZ. Fragmentation scoring by blinded analysis enabled further comparisons of
these profiles revealed increased levels of fragmented and decreased levels of tubular mitochondria in
both of the BTHS lines as compared to healthy controls. These fragmented mitochondrial profiles were
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significantly improved following treatment with AAV-TAZ in both BTHS lines, as shown in Figure 3I
and Figure S1.
Figure 3. Mitochondrial fragmentation in BTHS is reduced following AAV-TAZ treatment – IF showing
TOMM20 (red) staining for mitochondria, phalloidin (green) for cytoskeletal architecture, and DAPI
(blue) for cell nuclei. Representative IF images from untreated (A) healthy control, (B) BTHS1, and (C)
BTHS2 as well as AAV-TAZ-treated (D) healthy control, (E) BTHS1, and (F) BTHS2 fibroblast lines
(scale bar = 5 µm). (G) OMA, or (H) YME1L1 levels for each cell line following administration of
either the control AAV vector (light filled bars) or AAV-TAZ (dark hashed bars). OMA and YME1L1
levels were normalized to 18S gene expression for all samples. (I) Bar graph showing quantified
results from mitochondrial fragmentation scoring assay determining either extremely tubular, tubular,
or fragmented lengths for mitochondria. (Data are presented as mean + std. err. * p ≤ 0.05, ** p ≤ 0.01,
*** p ≤ 0.001.)
2.4. Impact of AAV-TAZ Treatment on Mitochondrial Function
An intracellular ATP quantitation assay was performed to measure relative ATP generation
between AAV-TAZ and AAV-eGFP-treated BTHS lines and healthy controls. The results showed
decreased ATP generation in both BTHS lines that was significantly increased in AAV-TAZ-treated
groups (Figure 4A). Next, a MTT assay was performed to further assess general metabolic activity
levels in each line. The MTT assay displayed similar results with reduced activities in BTHS lines as
compared to healthy controls that were significantly improved in AAV-TAZ-treated groups (Figure 4B).
Interestingly, assessments of ROS levels (as measured by a dihydroethidium (DHE)-based assay)
without rotenone showed that the significant increase in both BTHS1 and BTHS2 as compared to
healthy controls was ameliorated when the BTHS lines were treated with AAV-TAZ (Figure 4C,E).
However, when ROS levels were measured following the addition of rotenone, only the BTHS2 line
showed a significant increase in ROS as compared to healthy controls, although this difference was
also eliminated following AAV-TAZ treatment (Figure 4D,E). Evaluation of mitochondrial membrane
potentials (∆ψm) only revealed a significant difference between BTHS 2 and healthy cells without
AAV-TAZ treatment (Figure 4F).
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Figure 4. Mitochondrial function assays following AAV-TAZ treatment: (A) ATP generation,
(B) MTT levels, (C) ROS levels, (D) ROS levels (intracellular ROS derived from superoxide O2−)
following addition of rotenone. (E) Information from (C) and (D) combined into one graph, and (F)
TMRE (mitochondrial membrane potential levels) relative fluorescence levels from cells following
administration of control AAV-eGFP (light filled bars) and AAV-TAZ (dark hashed bars) vectors. (Data
are presented as mean + std. err. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.)
The seahorse extracellular flux–mitochondrial stress test was used to compare oxygen consumption
rates (OCR) between healthy and BTHS cells following treatment with either the AAV-eGFP control or
the AAV-TAZ therapeutic vectors (Figure 5A). The assay showed significant improvements in basal
and maximal OCR in both BTHS lines following AAV-TAZ treatment (Figure 5B,C). As observed in
the intracellular ATP quantitation assay, a significant increase in ATP production was also observed
in both BTHS lines following treatment with AAV-TAZ using the seahorse mitochondrial stress test
(Figure 5D). Both spare capacity and non-mitochondrial OCR ceased to be significantly decreased as
compared to healthy controls following treatment with the AAV-TAZ vector (Figure 5E,F).
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Figure 5. Seahorse extracellular flux mitochondrial stress test assay: (A) Profiles from all lines, (B) basal
OCR, (C) maximal OCR, (D) ATP generation, (E) spare capacity, and (F) non-mitochondrial OCR
from healthy controls and BTHS fibroblasts treated with either control AAV-eGFP (light filled bars) or
AAV-TAZ (dark hashed bars). (Data are presented as mean + std. err. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.)
3. Discussion
This study demonstrates that the reduced mtDNA copy numbers observed in primary BTHS
patient dermal fibroblasts can be efficiently recovered following AAV-mediated TAZ gene replacement.
As BTHS is primarily a disorder of IMM instability, these cells provide a unique mitochondrial
environment in which to assess mtDNA levels. The use of two BTHS lines representing mutations of
different severity in the TAZ locus (BTHS1—missense and BTHS2—a deletion resulting in a frameshift
and early stop codon) provides useful information regarding the potentially distinct impact of various
mutations on mitochondrial function as well as their respective responses to gene replacement.
In addition to differences in genetic severity, these primary fibroblast cells were derived from BTHS
patients who represent the phenotypic variability that exists in the BTHS population. The BTHS1
cells were isolated from a clinically mild patient who presented with decompensated cardiomyopathy
during the neonatal period that responded well to digoxin for one year and has had no further cardiac
disease for 40+ years. In contrast, the BTHS2 cells are derived from a patient who presented with dilated
cardiomyopathy, neutropenia, 3-methylglutaconic aciduria, and skeletal muscle weakness [6,17,18].
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As there is a critical need for the advancement of BTHS therapies, we have been developing an
AAV-TAZ gene replacement strategy. AAV is optimal for gene therapies designed to treat single gene
defects because the recombinant AAV (rAAV) used for gene delivery is a relatively nonpathogenic virus
(with all viral genes removed) that elicits a minimal immune response. Another attribute is its long-term
persistence as an episome within the nucleus of cells providing stable gene expression without risk of
insertional mutagenesis [22]. We have previously demonstrated successful in vivo AAV serotype 9
delivery of TAZ in a mouse model of BTHS that resulted in significant improvements in mitochondrial
function, heart and skeletal muscle function, whole-body activity levels, and global cardiac proteomic
profiles [19,20]. For this in vitro study, we took advantage of an AAV capsid we had previously
demonstrated to efficiently transduce primary canine dermal fibroblasts [23]. This AAV2 capsid’s
Y–F mutations enable more efficient transduction in vitro due to the lack of capsid ubiquitination and
improved intracellular trafficking to the nucleus [24].
Demonstrating the ability of our AAV-TAZ vector to restore mtDNA copy numbers in both BTHS
patient-derived fibroblast lines further validates AAV-mediated delivery of TAZ as a relevant therapy
for BTHS. Although many aspects involved in the response of mtDNA levels to various forms of
disease or stress states remain to be defined, one protein that may be of particular importance for
disorders impacting cardiac function is TMEM65. We recently discovered a significant downregulation
of TMEM65 protein levels in a multiplex, global proteomics study performed on hearts from a mouse
model of BTHS [20]. Other investigators have suggested that this protein (1) plays an important role in
the mitochondrial inner membrane where its expression is important for mitochondrial respiration and
maintenance of mtDNA copy numbers, and (2) is directly involved in the regulation of cardiac function
through Cx43 function in cardiomyocytes [25–27]. While more research is needed to fully understand
the contribution of TMEM65 levels to disease development, it is promising that in both the mouse model
of BTHS and the BTHS patient fibroblast study described here, we observed increased TMEM65 levels
following AAV-TAZ gene delivery that correspond well with various functional improvements [19,20].
Our evaluations demonstrated successful reduced expression of mitochondrial fragmentation
genes (YME1L1 andOMA) as well as a significant decrease in mitochondrial fragmentation. As increased
levels ofYME1L1 andOMA are associated with upregulation of mitochondrial fission and fragmentation
in response to various forms of cellular stress, successful downregulation of these genes represents
another positive downstream effect stemming from improved mitochondrial structure following
AAV-TAZ administration.
Significant improvements in ATP generation were observed in AAV-TAZ- treated cells as
demonstrated by both an intracellular ATP quantitation assay as well as calculated from seahorse
extracellular flux–mitochondrial stress tests. Finally, as a strong indication of overall improved
mitochondrial health, we found that AAV-TAZ administration improved basal and maximal
mitochondrial respiration in BTHS cells.
In sum, this study shows the ability of TAZ gene replacement to dramatically improve
mitochondrial structure, mtDNA copy numbers, and mitochondrial function in human BTHS cells
representing TAZ mutations of varied severity and supports further translation of AAV-mediated gene
therapy for BTHS into the clinical realm.
4. Methods
Fibroblast Culture Maintenance: De-identified human fibroblasts were approved for use under
IRB201400246. For maintenance, cells were grown at 37 ◦C in 5% CO2 in DMEM (Corning – Corning,
NY, USA 10-013CV) + 20% Fetal bovine serum (FBS) and 1% Pen/Strep.
EM Processing and Analyses: Fibroblasts were seeded onto round glass coverslips and
grown for two days. They were then rinsed in PBS 3× and placed in in Karnovsky’s fixative
(2% paraformaldehyde/2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer) and maintained
at 4 ◦C until processing. Sample embedding, sectioning, and scanning electron microscopy (SEM)
were performed by the Emory University Robert P. Apkarian Integrated Electron Microscopy Core.
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All measurement analyses were performed by laboratory personnel blinded to sample identities using
ImageJ software (NIH). Circularity was calculated as 4piArea/Perimeter2. Aspect ratios were calculated
as major axis/minor axis. Roundness was calculated as 4*Area/(piMajor Axis2). Solidity was calculated
as Area/Convex Area. n ≥ 50 mitochondria from a total of at least 10 EM images for each line.
AAV Mediated Transduction: a multiplicity of infection (MOI) of 50,000 viral genomes (v.g.) per
cell. They were incubated for seven days with medium changes every other day. Cells were then
detached, centrifuged at 49 g for 5 min, supernatant removed and pellets stored at −80 ◦C.
Taqman Gene Expression Analysis: Total RNA was isolated using Quick-RNA Mini-prep kit
(Zymo Research, Irvine, CA, USA) according to the manufacturer’s protocol. The gDNA was removed
using DNase I (Zymo Research). Quantitative real-time (RT)-PCR was performed on an Applied
Biosystems (Foster City, CA, USA) Step-One Plus Real-Time PCR System using Taqman primer/probes
designed (Table 2).
Table 2. Primers used in quantitative RT-PCR.
Gene Catalog Company
18S ribosomal RNA 18S Hs03003631-g1 Thermo Scientific
Tafazzin TAZ Hs00794094_m1 Thermo Scientific
YME1 like 1 ATPase YME1L1 Hs00907919-m1 Thermo Scientific
OMA1 zinc
metallopeptidase OMA1 Hs00377028-m1 Thermo Scientific
Relative mtDNA copy number: gDNA was isolated using a Quick-gDNA Mini-prep kit (Zymo
Research) according to the manufacturer’s protocol. Quantitative real-time (RT)-PCR was performed
on an Applied Biosystems Step-One Plus Real-Time PCR System using Taqman primer/probes designed
based upon previous studies (Table 3) [28,29].
Table 3. Primers used in quantitative RT-PCR.
Gene Catalog Company
AB mitochondrial gene 7S, encoding
D-loop, which is a replication start site of
the mtDNA
MT-7S HS02596861_s1 Thermo Scientific
Hemoglobin subunit beta HBB HS00758889_s1 Thermo Scientific
Immunofluorescence: Representative fibroblasts from each line and condition were seeded onto
glass coverslips and grown for 24 h. They were then rinsed three times in 1X PBS, fixed with 4%
paraformaldehyde, and maintained at 4 ◦C until processing. They were stained with TOMM20
anti-Rabbit (HPA011562, 1:200; Sigma-Aldrich, St. Louis, MO, USA) and Phalloidin (A12379, 1:200;
ThermoFisher - Life Technologies, Waltham, MA, USA) and mounted on microscope slides for imaging
with medium containing DAPI. All fragmentation analyses were performed by laboratory personnel
blinded to sample identities using ImageJ software (NIH). Fragmentation scores were calculated as
length of ≥ 30 mitochondria in each of 10 IF images for every line. The mitochondria were scored as
either fragmented (0–2 µM), tubular (2–3), or extensively tubular (3.5–5.0) (Table 4).
Table 4. Antibodies used in immunohistochemistry (I).
Protein Dilution (I) Company
Translocase of Outer Mitochondrial
Membrane 20 kDa protein TOMM20 1:200
Sigma Aldrich
#HPA011562
Phalloidin Alexa Fluor 488 1:200 Life Tech # A12379
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Determination of Mitochondrial Membrane Potential (TMRE – T669 ThermoFisher - Life
Technologies, Waltham, MA, USA): Mitochondrial membrane potential was measured using
tetramethylrhodamine methyl ester (TMRE). Cells were seeded at 30,000 cells per well in a 96-well
black bottom plate. After 24 h TMRE dye was added to the medium at 250 nM final concentration for
30 min. The membrane potential was normalized to total protein.
Intracellular ATP Quantification (ATPlite kit – 6,016,941 Perkin Elmer, Waltham, MA, USA):
Intracellular ATP production was measured by the ATPlite kit according to the manufacturer’s protocol.
ATP production was normalized to total protein as measured by DC protein assay kit for each sample.
MTT Assay (M2128 ThermoFisher - Life Technologies, Waltham, MA, USA ): The methyltetrazolium
bromide assay was used to determine mitochondrial dehydrogenase activity. Cells were seeded at
30,000 cells per well in a 96-well clear bottom plate. After 24 h MTT dye was added to the medium at
5 mg/mL for 2 h. The dehydrogenase activity was normalized to total protein.
Determination of Reactive Oxygen Species (D23107 ThermoFisher - Life Technologies, Waltham,
MA, USA ): Dihydroethidium (DHE) was used to determine reactive oxygen species production
(intracellular from superoxide) as previously described [23,30,31]. Cells were seeded at 30,000 cells
per well in a 96-well black bottom plate. After 24 h the medium was aspirated and half the wells
were treated with 10 µM of rotenone (a positive control for ROS production) and incubated for 1 h.
The medium was aspirated and all wells were washed with 1X-PBS. DHE was added to the medium at
a concentration of 5 µM and incubated for 20 min. ROS levels were normalized to total protein for
all samples.
Extracellular Flux Assay: Cells were seeded at a density of 30,000/80 µL per well in XF96-well
microplate (Seahorse Bioscience, Billerica, MA, USA) pre-coated with 25 µL per well of 0.1% gelatin.
Cells were incubated for 24 h into standard growth medium in a humidified incubator at 37 ◦C with 5%
CO2. After 24 h, the standard medium was exchanged by XF Base Medium pH 7.4 (Seahorse Bioscience)
supplemented with 25 mM glucose, 2 mM L-glutamine, and 1 mM sodium pyruvate. Subsequently,
were incubated for 30 min at 37 ◦C without CO2. OCR and ECAR were determined using XF Cell Mito
Stress Assay (Seahorse Bioscience) following additions of: (1) ATP synthase inhibitor: 1 µM oligomycin,
(2) uncoupler: 1 µM carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) and (3) Complex
I/II inhibitors: 0.5 µM Rotenone/Antimycin A. Data were analyzed using Wave Desktop Software
(Seahorse Bioscience) following the manufacturer’s instructions and normalized to protein levels.
Data Processing: Data analyses, graph creation, and statistical analyses were performed using
Sigma Plot Software. There were four biological replicates for each condition and experiment and each
biological sample was tested in triplicate. Descriptive statistics and paired t-tests were performed on
all data.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/14/3416/s1.
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